Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience
Authors:
- R.A. HajjehRHR.A. Hajjeh
- L. Privor-DummLPL. Privor-Dumm
- K. EdmondKEK. Edmond
- R. O’loughlinROR. O’loughlin
- S. ShettySSS. Shetty
- U.K. GriffithsUGU.K. Griffiths
- A.P. BearABA.P. Bear
- A.L. CohenACA.L. Cohen
- A. ChandranACA. Chandran
- A. SchuchatASA. Schuchat
- E.K. MulhollandEME.K. Mulholland
- M. SantoshamMSM. Santosham
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Accelerating Policy Decisions to Adopt Haemophilus influenzae Type b Vaccine: A Global, Multivariable AnalysisPLOS Medicine, 2010
- Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimatesThe Lancet, 2009
- Economic evaluations ofHaemophilus influenzaetype b vaccine: systematic review of the literatureExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Progress in Vaccination against Haemophilus influenzae type b in the AmericasPLOS Medicine, 2008
- Introduction of Hib vaccine into national immunization programmes: A descriptive analysis of global trendsVaccine, 2007
- Rapid Assessment Tool for Haemophilus influenzae type b Disease in Developing Countries1Emerging Infectious Diseases, 2004
- Global reduction of Hib disease: what are the next steps? Proceedings of the meetingThe Journal of Pediatrics, 2003
- Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countriesVaccine, 1999
- The introduction of new vaccines into developing countriesVaccine, 1999